Zhigang Xiong

Zhigang Xiong


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYing Luo
Ying Luo
YXYing Xue
Ying Xue
QLQun Lin
Qun Lin
LMLiyan Mao
Liyan Mao
GTGuoxing Tang
Guoxing Tang
Feng WangFeng Wang
Feng Wang
Background: The differential diagnosis between tuberculous meningitis (TBM) and bacterial meningitis (BM) remains challenging in clinical practice. This study aimed to establish a diagnostic model that could accurately distinguish TBM from BM.Methods: Patients with TBM or BM were recruited between January 2017 and January 2021 at Tongji Hospital (Qiaokou cohort) and Sino-French New City Hospital (Caidian cohort). The detection for indicators involved in cerebrospinal fluid (CSF) and T-SPOT assay were performed simultaneously. Multivariate logistic regression was used to create a diagnostic model.Results: A total of 174 patients (76 TBM and 98 BM) and another 105 cases (39 TBM and 66 BM) were enrolled from Qiaokou cohort and Caidian cohort, respectively. Significantly higher level of CSF lymphocyte proportion while significantly lower levels of CSF chlorine, nucleated cell count, and neutrophil proportion were observed in TBM group when comparing with those in BM group. However, receiver operating characteristic (ROC) curve analysis showed that the areas under the ROC curve (AUCs) produced by these indicators were all under 0.8. Meanwhile, tuberculosis-specific antigen/phytohemagglutinin (TBAg/PHA) ratio yielded an AUC of 0.889 (95% CI, 0.840–0.938) in distinguishing TBM from BM, with a sensitivity of 68.42% (95% CI, 57.30%–77.77%) and a specificity of 92.86% (95% CI, 85.98%–96.50%) when a cutoff value of 0.163 was used. Consequently, we successfully established a diagnostic model based on the combination of TBAg/PHA ratio, CSF chlorine, CSF nucleated cell count, and CSF lymphocyte proportion for discrimination between TBM and BM. The established model showed good performance in differentiating TBM from BM (AUC: 0.949; 95% CI, 0.921–0.978), with 81.58% (95% CI, 71.42%–88.70%) sensitivity and 91.84% (95% CI, 84.71%–95.81%) specificity. The performance of the diagnostic model obtained in Qiaokou cohort was further validated in Caidian cohort. The diagnostic model in Caidian cohort produced an AUC of 0.923 (95% CI, 0.867–0.980) with 79.49% (95% CI, 64.47%–89.22%) sensitivity and 90.91% (95% CI, 81.55%–95.77%) specificity.Conclusions: The diagnostic model established based on the combination of four indicators had excellent utility in the discrimination between TBM and BM.

29 October 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
GTGuoxing Tang
Guoxing Tang
MHMin Huang
Min Huang
YLYing Luo
Ying Luo
WLWei Liu
Wei Liu
QLQun Lin
Qun Lin
Feng WangFeng Wang
Feng Wang
Objectives: The longitudinal and systematic evaluation of immunity in coronavirus disease 2019 (COVID-19) patients is rarely reported.Methods: Parameters involved in innate, adaptive, and humoral immunity were continuously monitored in COVID-19 patients from onset of illness until 45 days after symptom onset.Results: This study enrolled 27 mild, 47 severe, and 46 deceased COVID-19 patients. Generally, deceased patients demonstrated a gradual increase of neutrophils and IL-6 but a decrease of lymphocytes and platelets after the onset of illness. Specifically, sustained low numbers of CD8+T cells, NK cells, and dendritic cells were noted in deceased patients, while these cells gradually restored in mild and severe patients. Furthermore, deceased patients displayed a rapid increase of HLA-DR expression on CD4+T cells in the early phase, but with a low level of overall CD45RO and HLA-DR expressions on CD4+and CD8+T cells, respectively. Notably, in the early phase, deceased patients showed a lower level of plasma cells and antigen-specific IgG, but higher expansion of CD16+CD14+proinflammatory monocytes and HLA-DR−CD14+monocytic-myeloid-derived suppressor cells (M-MDSCs) than mild or severe patients. Among these immunological parameters, M-MDSCs showed the best performance in predicting COVID-19 mortality, when using a cutoff value of ≥10%. Cluster analysis found a typical immunological pattern in deceased patients on day 9 after onset, which was characterized as the increase of inflammatory markers (M-MDSCs, neutrophils, CD16+CD14+monocytes, and IL-6) but a decrease of host immunity markers.Conclusions: This study systemically characterizes the kinetics of immunity of COVID-19, highlighting the importance of immunity in patient prognosis.

26 January 2024 in International Immunopharmacology
Verified
Journal Article
Open access
XWXiaochen Wang
Xiaochen Wang
GTGuoxing Tang
Guoxing Tang
YHYi Huang
Yi Huang
HSHuijuan Song
Huijuan Song
SZSiyu Zhou
Siyu Zhou
Feng WangFeng Wang
Feng Wang
The differential diagnosis between active tuberculosis (ATB) and latent tuberculosis infection (LTBI) is still a challenge worldwide. Immune indicators involved in innate, humoral, and cellular immune cells, as well as antigen-specific cells were simultaneously assessed in patients with ATB and LTBI. Of 54 immune indicators, no indicator could distinguish ATB from LTBI, likely due to an obvious heterogeneity of immune indicators noticed in ATB patients. Cluster analysis of ATB patients identified three immune clusters with different severity. Cluster 1 (42.1 %) was a ''Treg/Th1/Tfh unbalance type" cluster, whereas cluster 2 (42.1 %) was an "effector type'' cluster, and cluster 3 was a ''inhibition type'' cluster (15.8 %) which showed the highest severity. A prediction model based on immune indicators was established and showed potential in classifying Mycobacterium tuberculosis infection. We depicted the immune landscape of patients with ATB and LTBI. Three immune subtypes were identified in ATB patients with different severity.

15 October 2025 in Health Science Reports
Verified
Journal Article
Open access
HHHongyan Hou
Hongyan Hou
XYXu Yuan
Xu Yuan
RCRujia Chen
Rujia Chen
ZXZhigang Xiong
Zhigang Xiong
SWShiji Wu
Shiji Wu
Feng WangFeng Wang
Feng Wang
Background and Aims: Severe fever with thrombocytopenia syndrome virus (SFTSV) infection causes profound dysregulation of humoral immunity, leading to immunopathology and impaired viral clearance. However, the mechanisms underlying B cell dysfunction and inadequate antibody responses remain poorly defined. This review aims to summarize current evidence on B cell‐mediated immune dysregulation in SFTS and explore potential therapeutic implications. Methods: We conducted a comprehensive review of recent literature on humoral immunity in SFTS, including original research articles, autopsy reports, in vitro and single‐cell RNA‐sequencing studies. We focused on B cell subset alterations, antibody production kinetics, T follicular helper (Tfh) dysfunction, germinal center disruption, and viral immune evasion mechanisms. Results: SFTSV preferentially targets B cells, especially plasmablasts, which become hyperactivated and serve as potential viral reservoirs. Fatal cases show excessive plasmablast expansion but fail to mount virus‐specific IgG responses. Disrupted germinal center formation, impaired Tfh function, and a shift toward extrafollicular antibody responses contribute to low‐affinity antibody production and increased autoantibody generation. Cytokine storms further suppress B and Tfh cell function. Neutralizing antibody levels correlate with survival, and delayed IgG or absent anti‐Gn responses are associated with poor prognosis. Conclusion: SFTSV requires humoral immunity by inducing pathological plasmablast proliferation, impairing Tfh‐B cell interactions, and suppressing protective antibody responses. Understanding these mechanisms provides insight into SFTS pathogenesis and highlights potential therapeutic targets such as germinal center restoration, plasmablast modulation, and precision immunotherapy. Future strategies should focus on vaccine design targeting conserved viral epitopes and interventions that preserve long‐lived B cell immunity.